Leaflet ENTACAPONA MYLAN 200mg film-coated tablets


Indicated for: Parkinson's disease

Route of administration: oral

Substance: entacapone (antiparkinsonian agent)

ATC: N04BX02 (Nervous system | Dopaminergic agents | Other dopaminergic agents)

Entacapone is a medication used in the treatment of Parkinson's disease, administered together with levodopa to increase its effectiveness. It works by inhibiting an enzyme that breaks down levodopa in the body, thus prolonging its effect and improving motor fluctuations in patients.

Entacapone is taken orally, usually with each dose of levodopa, as directed by your doctor. It is important for the patient to follow the treatment schedule and not to stop administration without medical advice.

Side effects may include diarrhea, nausea, reddish-brown urine discoloration, fatigue, or involuntary movements. Rarely, allergic reactions or liver disorders may occur. Regular medical monitoring is recommended during treatment.

Entacapone helps control the symptoms of Parkinson's disease and improve quality of life, but requires correct administration and medical supervision to prevent complications.

General data about ENTACAPONA MYLAN 200mg

  • Substance: entacapone
  • Date of last drug list: 16-08-2017
  • Commercial code: W57891015
  • Concentration: 200mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 300
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Combinations with other substances